In this article, we will look at the 7 Fastest Growing European Stocks to Invest In.
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade. The more interesting shift is that the region is starting to look better on its own terms. Fidelity says, “The case for Europe has strengthened considerably,” adding that “Falling inflation, lower interest rates, and fiscal support all provide a supportive backdrop for corporate investment and consumer confidence.” Faster-growing companies have a better setup when financing conditions are easing, and business confidence is improving. Fidelity also makes an important distinction, saying “European companies should not be seen as proxies for the region’s economy. They are global businesses with resilient balance sheets and proven growth profiles.” The argument is not simply that Europe is recovering. It is that many European-listed companies can still grow faster than the region.
Schroders adds a more immediate market angle. In its February 2026 fund update, the firm says “European shares gained in February, benefitting from signs of an economic pick-up in the region and ongoing rotation away from US shares.” That suggests investors are already beginning to reposition as Europe’s backdrop improves. Schroders also notes that “Value remains extremely attractively priced,” with “international Value stocks trade below long run multiples, and UK valuations are at historically low levels.” When a market is still priced conservatively, but the growth picture is improving, faster-growing companies in that market can stand out even more.
Taken together, these reports suggest Europe is no longer just a catch-up or valuation story. It is increasingly a region where improving macro conditions, stronger investor flows, and globally exposed businesses are creating room for growth stocks to get more attention. With that in mind, we will look at the 7 Fastest-Growing European Stocks to Invest In.
Our Methodology
We used the Finviz screener to identify European stocks that have achieved more than 50% sales growth over the past three years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. Ascendis Pharma A/S (NASDAQ:ASND)
On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced positive Week 52 topline results from the Phase 2 New InsiGHTS trial evaluating once-weekly TransCon hGH against daily somatropin in prepubertal children with Turner syndrome. At Week 52, annualized height velocity was similar between the two groups, with an LS mean of 9.05 cm/year for TransCon hGH-treated children versus 9.04 cm/year for daily somatropin. The company also said TransCon hGH showed a safety and tolerability profile similar to daily somatropin through follow-up of up to 143 weeks, with adverse events reported as mild to moderate and no discontinuations due to adverse events.
On March 16, 2026, Jefferies assumed coverage of Ascendis Pharma A/S with a Buy rating and a $290 price target, describing the company as a “two-engine growth story” with Yorvipath on a “hot growth trajectory” and Yuviwel positioned to “disrupt” achondroplasia in the near term.
On the same day, the company announced new data from its pivotal ApproaCH trial showing that children with achondroplasia treated with once-weekly TransCon CNP maintained growth improvements through Week 104, with further gains in body proportionality during the second year of treatment. Ascendis said TransCon CNP, approved by the U.S. FDA in February 2026 under the trade name YUVIWEL, remains under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026.
Ascendis Pharma A/S develops TransCon-based therapies for unmet medical needs.
6. BeOne Medicines AG (NASDAQ:ONC)
On March 26, 2026, Wolfe Research analyst Kalpit Patel initiated coverage on BeOne Medicines AG (NASDAQ:ONC) with an Outperform rating and a $340 price target, saying the company runs one of the broadest development programs in biotech. The analyst highlighted Brukinsa as a “category-leading flagship drug” alongside a “credible” pipeline, adding that concerns around fixed-duration therapies appear “overdone” and could present a buying opportunity.
On March 23, 2026, BeOne Medicines AG received orphan drug designation from the FDA for its hepatocellular carcinoma treatment.
On March 16, 2026, Jefferies analyst Faisal Khurshid downgraded BeOne Medicines AG to Hold from Buy with a $290 price target, down from $420, stating that while Brukinsa remains a leading hematology asset, the stock “is not mispriced” at current levels. The firm added that leadership in chronic lymphocytic leukemia is already reflected, with future growth drivers expected to play out more gradually.
BeOne Medicines AG develops oncology treatments across global markets.
5. Autolus Therapeutics plc (NASDAQ:AUTL)
On March 31, 2026, Mizuho lowered its price target on Autolus Therapeutics plc (NASDAQ:AUTL) to $10 from $12 previously and maintained an Outperform rating on the company shares after updating its models across its small-cap biotech coverage following the fourth quarter earnings reports.
On March 27, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) reported fourth quarter EPS of (34c), compared to the (43c) consensus estimate, with revenue of $24.29 million versus $23.29 million consensus. Chief Executive Officer Christian Itin said that Autolus Therapeutics plc (NASDAQ:AUTL) had a “strong first year of launch” for AUCATZYL in the U.S., highlighting the commercial execution, product delivery, and real-world data showing clinical activity with low rates of high-grade CRS and ICANS. Chief Executive Officer Christian Itin added that the positive customer experience should support the future growth of AUCATZYL.
Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally.
4. Galapagos NV (NASDAQ:GLPG)
On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to Ouro’s clinical-stage asset gamgertamig, a BCMAxCD3 T cell engager, along with additional preclinical programs. Under the agreement, Galapagos will obtain licenses to key intellectual property, assume certain development responsibilities, and gain operational assets including facilities and personnel, effectively establishing an operating business tied to the programs. The framework also allows Galapagos to deploy at least $500M of its cash independently, including up to $150M for potential share buybacks.
Gamgertamig has received Fast Track and Orphan Drug Designation from the FDA for AIHA and ITP and is expected to enter registrational studies as early as 2027. Galapagos will fund early-stage development, while later-stage costs will be shared with Gilead, which will lead global commercialization outside certain territories. The company is also eligible for milestone payments and tiered royalties ranging from 20% to 23% on net sales.
On March 26, 2026, Galapagos NV also announced the proposed appointment of Gino Santini as a non-executive independent director and future chair of the board, subject to shareholder approval at its April 28 annual meeting.
Galapagos NV develops therapies focused on oncology and immunology.
3. Nyxoah SA (NASDAQ:NYXH)
On March 23, 2026, Baird analyst David Rescott lowered the price target on Nyxoah SA (NASDAQ:NYXH) to $4.62 from $5.87 and maintained a Neutral rating, citing model updates as the company’s U.S. rollout begins to gain traction but remains in its early stages.
On March 20, 2026, Stifel lowered its price target on Nyxoah SA to $10 from $11 previously and maintained a Buy rating, noting model adjustments tied to several moving parts.
On March 19, 2026, Nyxoah SA reported Q4 EPS of (EUR 0.59), compared to (EUR 0.46) a year ago, with revenue of EUR 5.64M versus EUR 1.26M last year. Chief Executive Officer Olivier Taelman said the quarter marked the company’s first full period of U.S. commercialization, with revenue exceeding expectations and positive feedback from surgeons and patients, alongside consistent reimbursement from major payors and Medicare.
The company expects U.S. net revenue to grow approximately 25% sequentially in both Q1 and Q2 of 2026, while international revenue is expected to follow typical seasonal patterns.
Nyxoah SA develops neurostimulation therapies to treat obstructive sleep apnea.
2. Bicycle Therapeutics plc (NASDAQ:BCYC)
On March 18, 2026, RBC Capital lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $7 from $11 and maintained a Sector Perform rating, citing the company’s pivot away from zelenectide as a near-term setback that reduces visibility toward commercialization, though restructuring efforts could generate meaningful cost savings and support a longer-term reset.
On the same day, Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $36 from $44 and maintained an Outperform rating, noting the company’s decision to deprioritize zelenectide-pevedotin despite encouraging data, with resources being redirected toward BT5528 and next-generation programs, including its radio-conjugates portfolio.
On March 17, 2026, Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of (29c), compared to the (95c) consensus estimate, with revenue of $47.96M versus $7.08M consensus. The company said the increase in revenue was primarily driven by recognition of remaining collaboration revenue following termination notices with partners, including Novartis and Bayer. CEO Kevin Lee said the company completed dose selection in the Duravelo-2 trial but, following regulatory feedback, decided to deprioritize zelenectide for internal development and shift focus toward other pipeline programs, alongside a broader strategic reprioritization that includes a proposed workforce reduction.
Bicycle Therapeutics plc (NASDAQ:BCYC) develops novel therapeutics for diseases with limited treatment options.
1. Marex Group plc (NASDAQ:MRX)
On March 27, 2026, TD Cowen raised the price target on Marex Group plc (NASDAQ:MRX) to $66 from $61 and maintained a Buy rating, saying updates from the company’s investor day could help support a higher valuation multiple, which the firm views as depressed.
Also on March 27, 2026, Barclays raised its price target on Marex Group plc (NASDAQ:MRX) to $55 from $50 and maintained an Overweight rating following the investor day. The firm said management struck a “confident tone” on the outlook, pointing to multiple growth drivers and potential margin upside from AI-related initiatives, while noting preliminary Q1 expectations appear ahead of Street estimates.
On March 26, 2026, Marex Group plc (NASDAQ:MRX) guided Q1 revenue to $667M-$697M versus the $588.75M consensus and sees adjusted profit before tax of $140M-$150M. The company said it expects record profitability, driven by elevated market volatility and continued growth in client balances, which averaged around $16 billion during the quarter.
Marex Group plc (NASDAQ:MRX) provides liquidity and market infrastructure services across commodity and financial markets.
READ NEXT: 7 Heavily-Battered Consumer Stocks That Could Triple by 2027 and 10 Best 52-Week Low NYSE Stocks to Buy Now
Hedge Fund Resource Center